Long acting risperidone in treatment of schizophrenia:A retrospective study

: Objective: In this study it is aimed to investigate the efficacy of long- acting risperidone in treatment of schizophrenia. Method: The files of patients whom diagnosed schizophrenia according to DSM IV and had been treated with long acting risperidone in Gaziantep University School of Medicine Department of Psychiatry, Pscyhotic Disorders Unit, was investigated retrospectively. Results: End of the study clinical improvement was achieved by 66.7% (20/30). In the course of 6 months follow up period, weight gain in 2 patients (6.6%), tardive dyskinesia in 1 patient (3.3%), oculogyric crisis (3.3%), and akathisia in 1 patient (3.3%) was observed. Conclusion: This is the first study in Turkey which evaluates the efficacy of long-acting risperidone treatment for 24 weeks period and long-acting risperidone was appeared lead to clinical improvement in proportion %66.7 especially for schizophrenia patients with partial compliance.

[1]  S. Selek,et al.  Atypical antipsychotics as “mood stabilizers”: A retrospective chart review , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[2]  J. Kahn,et al.  Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone , 2007, International clinical psychopharmacology.

[3]  S. Selek,et al.  Atypical antipsychotics related metabolic syndrome in bipolar patients. , 2007, Journal of affective disorders.

[4]  J. Lindenmayer,et al.  Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder , 2007, European Neuropsychopharmacology.

[5]  M. Valenstein,et al.  Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. , 2006, The Journal of clinical psychiatry.

[6]  S. Selek,et al.  Acute dystonia after initial doses of ziprasidone: A case report , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[7]  J. Kane,et al.  Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection , 2005, Schizophrenia Research.

[8]  J. Lauriello,et al.  Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia , 2005, Schizophrenia Research.

[9]  B. Remmerie,et al.  Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia , 2004, Schizophrenia Research.

[10]  R. Love,et al.  Long-acting risperidone injection. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[11]  J. Lindenmayer,et al.  Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. , 2004, The Journal of clinical psychiatry.

[12]  M. Turner,et al.  Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone , 2004, European Psychiatry.

[13]  G. Remington,et al.  Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. , 2003, The Journal of clinical psychiatry.

[14]  S. Keith,et al.  Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. , 2003, The American journal of psychiatry.

[15]  J. Lieberman,et al.  Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. , 1999, Archives of general psychiatry.

[16]  M. Livingston,et al.  Risperidone , 1994, The Lancet.

[17]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.